Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03924414 · ClinicalTrials.gov registry record · Phase 4

Trial of Parkinson's And Zoledronic Acid

A Phase 4 study of Parkinson Disease and Osteoporosis, sponsored by California Pacific Medical Center Research Institute.

Active
Registry status
Phase 4
Development phase
2,650
Enrollment target
20
Study locations

NCT03924414: Active Phase 4 study of Parkinson Disease and Osteoporosis, sponsored by California Pacific Medical Center Research Institute.

NCT03924414 is a Phase 4 study of Parkinson Disease and Osteoporosis that is active but no longer recruiting, run by California Pacific Medical Center Research Institute. The registered enrollment target is 2,650 participants, below the 5,317-participant average among 297 other Parkinson Disease trials with a reported enrollment target (50% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03924414, a Phase 4 study of Parkinson Disease and Osteoporosis, is active but no longer recruiting, sponsored by California Pacific Medical Center Research Institute.

ACTIVE NOT RECRUITING
Registry status
Phase 4
Development phase
2,650 participants
Enrollment target
20
Study locations

Study Summary

This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and parkinsonism with at least 2 years of follow-up. A total of 2650 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the National Institute of Aging.

Primary Outcome

All clinical fractures

Conditions Studied

Parkinson Disease Osteoporosis Multiple System Atrophy Dementia With Lewy Bodies Progressive Supranuclear Palsy Parkinson's Disease and Parkinsonism Parkinsonism Vascular Parkinsonism Atypical Parkinsonism

Interventions

  • OTHER Placebo
  • DRUG Zoledronic Acid 5Mg/Bag 100Ml Inj

Study Locations (20)

California

  • Sutter Health - Berkeley
  • Parkinson's and Movement Disorder Institute - Fountain Valley
  • University of California, Irvine - Irvine
  • Loma Linda University - Loma Linda
  • Cedars-Sinai Medical Center - Los Angeles
  • University of California, Los Angeles - Los Angeles
  • Valley Parkinson Clinic - Los Gatos
  • Parkinson's Disease and Movement Disorder Center of Silicon Valley - Palo Alto
  • University of California, Riverside - Riverside
  • Sutter Health - Sacramento
  • University of California, Davis - Sacramento
  • University of California, San Francisco - San Francisco

Connecticut

  • University of Connecticut - Farmington
  • University of Connecticut - Farmington
  • Hartford Healthcare - Hartford

Arkansas

  • Washington Regional Medical Center - Fayetteville
  • University of Arkansas for Medical Sciences - Little Rock

Colorado

  • University of Colorado, Denver - Aurora
  • St. Mary's Medical Center - Grand Junction

Arizona

  • Mayo Clinic - Scottsdale

Trial Details

FieldValue
Enrollment Target 2,650 participants
Start Date 2019-11-15
Est. Completion 2025-10-31
Phase Phase 4
California Pacific Medical Center Research Institute

29 total trials

What the registry record for NCT03924414 still lists

NCT03924414 is an interventional study that assigns participants to a tested intervention. Its 2,650 participants enrollment target places it among the larger protocols in the corpus, below the 5,317-participant average among 297 other Parkinson Disease trials with a reported enrollment target (50% lower).

The record links to 9 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT03924414 names 20 study sites across 5 states, led by California, Connecticut, Arkansas.

Frequently Asked Questions

What is clinical trial NCT03924414 about?

NCT03924414 is a clinical study titled "Trial of Parkinson's And Zoledronic Acid". This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and parkinsonism with at least 2 years of follow-up. A total of 2650 participants w...

What is the current status of trial NCT03924414?

This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 2,650 participants. The study started on 2019-11-15. Estimated completion is 2025-10-31.

What conditions does trial NCT03924414 study?

This clinical trial studies the following conditions: Parkinson Disease, Osteoporosis, Multiple System Atrophy, Dementia With Lewy Bodies, Progressive Supranuclear Palsy.

What interventions are being tested in trial NCT03924414?

The interventions under investigation include: Placebo (OTHER), Zoledronic Acid 5Mg/Bag 100Ml Inj (DRUG).

Who is sponsoring clinical trial NCT03924414?

This trial is sponsored by California Pacific Medical Center Research Institute, which has 29 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03924414 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Parkinson Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03924414's enrollment target sits among peer trials

2,650 8th of 297 higher than 290 of 297 other Parkinson Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06825715 · 2,653 participants · NA

    Multilevel Intervention for Precision Oncology

  • NCT06455085 · 2,634 participants · NA

    RESTORE: REducing Future fractureS and Improving ouTcOmes of fRagility fracturE

  • NCT05471908 · 2,674 participants · NA

    Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial

  • NCT05111925 · 2,690 participants

    Pre- and Post-neuromusculoskeletal Injury Risk Evaluation for Return-to-Duty Enhancement

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03924414, the US trial registry maintained by the National Library of Medicine. NCT03924414 (large enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.